Kyowa Kirin Announces EU Approval for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH)

TOKYO–(BUSINESS WIRE)–Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced that CRYSVITA® (burosumab) has been approved for the option of self-administration in the European Union (EU) for… Read full article

Leave a comment

Your email address will not be published. Required fields are marked *